Tickers

1. Composite Trajectory Verdict

For a pre-revenue biotechnology company, the cash flow statement and balance sheet (liquidity and runway) carry the most weight because operations are entirely funded by equity issuances and investment income, with no product revenue to offset cash burn.

Composite Trajectory: Mixed

Earnings show a consistent improvement: net losses and operating expenses have decreased year-over-year in both the full fiscal year and the most recent nine- and six-month periods. Cash flow is mixed: operating cash burn remains substantial and was slightly higher in the nine months ended July 2026 versus the prior year, but financing inflows from ATM offerings have increased significantly, resulting in a modest net cash increase in recent interim periods. The balance sheet is deteriorating: cash and short-term investments have declined steadily from $19.9M (October 2024) to $15.2M (October 2025) to $13.9M (July 2026), total equity has fallen, and the accumulated deficit continues to grow, even as liabilities also decline.

2. Red Flags

• No revenue in any reported period; the company states it does not expect to generate revenue from therapeutics or vaccines in the near term and relies on legacy patent licensing that is not currently producing income (10-K 2025-10-31, MD&A Revenue; 10-Q 2026-07-31, MD&A Revenue).
• Cash and short-term investments have declined consistently: $19.9M at October 31, 2024 → $15.2M at October 31, 2025 → $13.9M at July 31, 2026 (10-K 2025-10-31, MD&A Liquidity; 10-Q 2026-07-31, MD&A Liquidity; 10-Q 2026-04-30, MD&A Liquidity).
• Accumulated deficit growing: -$240.8M (Oct 2024) → -$251.7M (Oct 2025) → -$259.4M (Jul 2026) (10-K 2025-10-31, Consolidated Balance Sheets; 10-Q 2026-07-31, Condensed Consolidated Balance Sheets; 10-Q 2026-04-30, Condensed Consolidated Balance Sheets).
• Operating cash flow remains deeply negative with no clear improvement: -$7.17M (FY2025) vs -$7.34M (FY2024); nine months FY2026 -$6.12M vs -$5.92M (prior year) (10-K 2025-10-31, Consolidated Statements of Cash Flows; 10-Q 2026-07-31, Consolidated Statements of Cash Flows).
• Heavy reliance on at-the-market equity offerings to fund operations: $2.38M raised in FY2025, $4.81M in nine months FY2026, $2.87M in six months FY2026, driving share count from 32.2M (Oct 2024) to 34.6M (Jul 2026) (10-K 2025-10-31, MD&A Liquidity; 10-Q 2026-07-31, MD&A Liquidity; 10-Q 2026-04-30, MD&A Liquidity; 10-Q 2026-07-31, Condensed Consolidated Statements of Equity).
• Interest income declining as short-term investment balances and rates fall: $1.13M (FY2024) → $0.67M (FY2025); nine months FY2026 $0.35M vs $0.52M (prior year) (10-K 2025-10-31, Consolidated Statements of Operations; 10-Q 2026-07-31, Condensed Consolidated Statements of Operations).
• Noncontrolling interest deficit widening: -$1.11M (Oct 2024) → -$1.21M (Oct 2025) → -$1.27M (Jul 2026) (10-K 2025-10-31, Consolidated Balance Sheets; 10-Q 2026-07-31, Condensed Consolidated Balance Sheets).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Overall Assessment: Net losses have narrowed across every comparable period. The FY2025 net loss was $11.0M versus $12.7M in FY2024 (10-K 2025-10-31, Consolidated Statements of Operations). For the nine months ended July 31, 2026, net loss was $7.75M versus $8.31M in the prior-year period (10-Q 2026-07-31, Condensed Consolidated Statements of Operations). For the six months ended April 30, 2026, net loss was $5.12M versus $6.03M in the prior-year period (10-Q 2026-04-30, Condensed Consolidated Statements of Operations). Total operating expenses decreased in each comparable period: FY2025 $11.7M vs $13.8M; nine months FY2026 $8.10M vs $8.83M; six months FY2026 $5.36M vs $6.39M (same sources). Both R&D and G&A expenses contributed to the decline. Revenue remained $0 in all periods.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Overall Assessment: Operating cash burn was roughly flat year-over-year for the full fiscal year (-$7.17M vs -$7.34M) and for the six-month period (-$4.35M vs -$4.41M), but worsened in the nine-month period (-$6.12M vs -$5.92M) (10-K 2025-10-31, Consolidated Statements of Cash Flows; 10-Q 2026-07-31, Consolidated Statements of Cash Flows; 10-Q 2026-04-30, Consolidated Statements of Cash Flows). Investing cash inflows from short-term investment maturities declined significantly in the interim periods (nine months FY2026 $1.41M vs $4.21M; six months FY2026 $1.65M vs $5.05M). Financing cash inflows increased markedly due to larger ATM equity raises: nine months FY2026 $4.87M vs $1.93M; six months FY2026 $2.93M vs $0.001M. Net cash change was slightly positive in the interim periods (+$154K nine months, +$233K six months) but the cash and short-term investment balance continued to decline from $15.2M at October 31, 2025 to $13.9M at July 31, 2026.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Overall Assessment: Total assets fell from $21.6M (Oct 2024) to $16.1M (Oct 2025) to $15.1M (Jul 2026) (10-K 2025-10-31, Consolidated Balance Sheets; 10-Q 2026-07-31, Condensed Consolidated Balance Sheets; 10-Q 2026-04-30, Condensed Consolidated Balance Sheets). Cash and short-term investments, the primary liquid assets, declined from $19.9M to $15.2M to $13.9M over the same intervals. Total shareholders' equity decreased from $20.0M to $15.2M to $14.5M, while the accumulated deficit deepened from -$240.8M to -$251.7M to -$259.4M. Additional paid-in capital rose from $260.4M to $266.5M to $273.5M, reflecting equity issuances. Total liabilities declined modestly from $2.70M to $2.13M to $1.87M, mainly from lease liability reductions. The net effect is a shrinking equity base and declining liquidity.

6. Data Gaps

• Standalone Q1 FY2026 (three months ended January 31, 2026) financial statements (10-Q 2026-01-31 referenced but not provided).
• Standalone Q3 FY2025 (three months ended July 31, 2025) financial statements (10-Q 2025-07-31 referenced but not provided).
• Full fiscal year 2026 results (not yet filed).
• Revenue breakdown by source (company reports $0 revenue in all periods).
• Debt maturity schedule beyond the operating lease (no debt instruments reported).
• Segment-level cash flow statements (only segment operating expenses provided).